Basecamp Research, a London-based artificial intelligence company focused on drug discovery and therapeutics, has secured $140 million in Series C funding, bringing its total capital raised to $225 million since its founding in 2019.
The funding round was led by S32, with participation from a diverse investor consortium spanning technology giants, venture capital firms, and government-backed funds. Nvidia’s venture arm NVentures and Anthropic’s Anthology Fund joined the round, reflecting growing confidence in AI-driven approaches to pharmaceutical development. The investment also attracted backing from the NATO Innovation Fund and the UK Sovereign AI Fund, signalling support from geopolitical stakeholders keen on strengthening scientific capabilities.
Additional investors in the round included Catalio, the Rockefeller Foundation, European Tech Collective, Firebrand, River Capital, King Philanthropies, and Redalpine, demonstrating broad-based confidence in the company’s mission and execution.
Advancing AI-Designed Therapeutics
Basecamp Research intends to deploy the capital to train a new generation of artificial intelligence models and accelerate its pipeline of AI-designed therapeutics toward clinical development. The company operates at the intersection of computational biology and drug discovery, leveraging machine learning to identify and develop novel therapeutic candidates.
Glen Gowers, speaking on behalf of the company, articulated the vision driving the investment: “We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how. AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”
The funding comes at a time when AI applications in life sciences are attracting unprecedented levels of investment globally. Traditional pharmaceutical development cycles remain lengthy and costly, creating an opportunity for computational approaches to compress timelines and improve success rates.
European Context
The investment underscores London’s continued prominence as a hub for AI-driven life sciences innovation. While the broader European startup ecosystem faces headwinds from macroeconomic pressures and venture capital consolidation, specialized sectors like computational drug discovery continue to attract international capital.
The participation of institutions such as the UK Sovereign AI Fund and NATO Innovation Fund suggests policymakers view pharmaceutical innovation as strategically important. Similarly, the backing from European investors like Redalpine and European Tech Collective reflects growing recognition that AI-enabled drug development could become a competitive advantage for Europe’s scientific and industrial base.
Basecamp Research’s funding success illustrates how European founders and companies tackling fundamental challenges in healthcare can access global capital when combining technical expertise with clear commercial potential and societal impact.